Cor Therapeutics Integrilin

Executive Summary

Sales of the GP IIb/IIIa antagonist totaled $63.7 mil. in 1999. The market Aclearly has a $1.5 bil. potential,@ CEO Vaughn Kailian maintained at Chase H&Q. Cor has identified growth opportunities for earlier usage in patients already being treated with Integrilin, as well as additional use in urgent patients. Currently 60% of Integrilin use is in patients undergoing elective procedures, and 40% is in urgent patients. Cor intends Ato ensure that we increase our penetration, increase our usage length of time, and increase our distribution in the US.@ Currently, out of 2,400 facilities where the product could potentially be used, Integrilin is Aprobably being used in half of those hospitals,@ Kailian said. Cor is planning to unblind a study on the use of Integrilin in the setting of angioplasty and stents during the 2nd quarter